Latest Period
Q2 2026
Security Snapshot
Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) Institutional Ownership
CUSIP: 640979100
13F Institutional Holders and Ownership History from Q3 2023 to Q2 2026
Institutions Reporting
111
Shares (Excl. Options)
75,989,951
Price
$1.70
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- NMRA on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 75,989,951
- Total 13F value
- $129,208,696
- Portfolio coverage rank
- 0%
- Share change
- +5,552,478
- Value change
- +$7,005,705
- Number of holders
- 111
- Shares outstanding
- 186,788,806
- SEC-reported price per share
- $1.63
- Insider filing price
- $1.63
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- NMRA - Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 640979100.
- 111 institutions reported positions in Q2 2026.
- 5 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 112 to 111 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $137,245,288 to $129,208,696.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 111 institutions filings for Q2 2026.
Security key
640979100
Latest holder period
Q2 2026
13F holders
111
13D/G owners
5
CIK / CUSIP context first
Open Q2 2026 holders
NMRA full holder history
Neumora Therapeutics, Inc. SEC filings
Neumora Therapeutics, Inc. company facts
Neumora Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 640979100:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
5
Security
NMRA
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 19% | -9.5% | $69,289,455 | +$13,162 | 33,965,419 | +0.02% | Kristina Burow | 30 Mar 2026 |
| Invus Global Management, LLC | 4.7% | -14% | $16,570,753 | -$975,000 | 8,497,822 | -5.6% | Raymond Debbane | 31 Mar 2026 |
| BERNS PAUL L | 5.1% | $6,334,229 | 8,226,272 | Paul L Berns | 31 Dec 2024 | |||
| K2 HealthVentures Equity Trust LLC | 3.1% | -38% | $11,291,383 | -$6,252,835 | 5,790,453 | -36% | K2 HealthVentures Equity Trust LLC | 31 Mar 2026 |
| FMR LLC | 2.2% | $2,692,163 | 3,496,316 | FMR LLC | 31 Mar 2025 |
As of 30 Jun 2026, 111 institutional investors reported holding 75,989,951 shares of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA). This represents 41% of the company’s total 186,788,806 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
35%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Siren, L.L.C. | 4.5% | 8,497,822 | 0% | 0.29% | $14,446,297 |
| BlackRock, Inc. | 4.2% | 7,791,869 | +279% | 0% | $13,246,178 |
| SOFTBANK GROUP CORP. | 3.3% | 6,090,301 | 0% | 0.06% | $10,353,512 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.5% | 4,669,585 | +20% | 0% | $7,938,295 |
| MIC Capital Management UK LLP | 2.4% | 4,460,700 | 0% | 1.9% | $7,583,190 |
| FMR LLC | 1.9% | 3,498,869 | +0.01% | 0% | $5,948,077 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 1.8% | 3,309,123 | 0% | 0.06% | $5,625,509 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.4% | 2,607,289 | +140% | 0% | $4,433,341 |
| ICONIQ Capital, LLC | 1.4% | 2,559,090 | 0% | 0.13% | $4,350,453 |
| TWO SIGMA INVESTMENTS, LP | 1.2% | 2,244,829 | +10% | 0% | $3,816,209 |
| ORBIMED ADVISORS LLC | 1.1% | 2,139,882 | 0.07% | $3,637,799 | |
| Lunate Capital Ltd | 1.1% | 2,124,143 | 0% | 1.8% | $3,611,043 |
| Boxer Capital Management, LLC | 1.1% | 2,000,000 | 0.26% | $3,400,000 | |
| JOHNSON & JOHNSON | 0.99% | 1,849,445 | 0% | 0.39% | $3,144,057 |
| STATE STREET CORP | 0.85% | 1,582,119 | +297% | 0% | $2,689,602 |
| TUDOR INVESTMENT CORP ET AL | 0.73% | 1,356,147 | +76% | 0.01% | $2,305,450 |
| Ikarian Capital, LLC | 0.68% | 1,278,408 | 0% | 0.36% | $2,173,294 |
| RENAISSANCE TECHNOLOGIES LLC | 0.68% | 1,262,304 | -9.1% | 0% | $2,145,917 |
| Affinity Asset Advisors, LLC | 0.57% | 1,070,651 | 0.09% | $1,820,107 | |
| MARSHALL WACE, LLP | 0.48% | 904,458 | -24% | 0% | $1,537,579 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 0.48% | 894,791 | +384% | 0% | $1,521,145 |
| CITADEL ADVISORS LLC | 0.44% | 828,933 | +141% | 0% | $1,409,187 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.44% | 823,583 | +60% | 0% | $1,400,091 |
| NORTHERN TRUST CORP | 0.43% | 800,571 | +307% | 0% | $1,360,971 |
| Ensign Peak Advisors, Inc | 0.42% | 784,679 | 0% | $1,333,954 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
12
Latest
Q2 2026
Rows shown
1-12 of 12
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 75,989,951 | $129,208,696 | +$7,005,705 | $1.70 | 111 |
| 2026 Q1 | 70,388,932 | $137,245,288 | +$14,527,234 | $1.95 | 112 |
| 2025 Q4 | 62,936,237 | $112,659,237 | +$21,661,237 | $1.79 | 101 |
| 2025 Q3 | 50,688,208 | $92,241,263 | -$7,574,740 | $1.82 | 91 |
| 2025 Q2 | 56,105,109 | $41,177,547 | -$6,520,439 | $0.73 | 96 |
| 2025 Q1 | 65,233,736 | $65,235,367 | -$163,396,114 | $1.00 | 111 |
| 2024 Q4 | 80,333,766 | $851,575,296 | +$93,329,557 | $10.60 | 132 |
| 2024 Q3 | 68,678,182 | $907,013,068 | +$21,361,695 | $13.21 | 103 |
| 2024 Q2 | 63,827,298 | $627,414,966 | +$100,142,866 | $9.83 | 92 |
| 2024 Q1 | 52,696,596 | $725,374,900 | +$114,726,209 | $13.75 | 86 |
| 2023 Q4 | 43,747,888 | $744,815,306 | +$130,275,365 | $17.05 | 60 |
| 2023 Q3 | 36,353,167 | $512,042,809 | +$512,042,809 | $14.11 | 38 |